Journal
NEUROPSYCHIATRIC DISEASE AND TREATMENT
Volume 16, Issue -, Pages 263-271Publisher
DOVE MEDICAL PRESS LTD
DOI: 10.2147/NDT.S239763
Keywords
schizophrenia; kynurenic acid; cognitive impairment; symptom
Categories
Funding
- National Natural Science Foundation of China [81571333]
- Science and Technology Department of Guangdong Province Major Science and Technology [2016B010108003]
- China Postdoctoral Science Foundation [2018M640769]
- National Key Technology Research and Development Program of the Ministry of Science and Technology of China [2015BAI13B01]
- National Science and Technologic Program of China [2015BAI13B02]
- Science and Technology Program of Guangzhou [201807010064, 201704020168]
- Science and Technology Program of Guangdong [2016A020216004]
- Guangzhou medical and health science and technology project [20171 A011268, 20181A011044]
- Science and Technology Plan Project of Guangdong Province [2019B030316001]
- Guangzhou Municipal Psychiatric Diseases Clinical Transformation Laboratory [20180501 0009]
Ask authors/readers for more resources
Objective: Preclinical studies have reported that abnormal kynurenic acid (KYNA) may play a role in cognitive deficits. Schizophrenia (SCZ) is characterized by a wide range of cognitive deficits that may evolve from abnormal KYNA. This study aimed to explore the relationship between KYNA and cognitive impairment in SCZ, which has not yet been reported. Methods: We recruited 30 SCZ patients and 34 healthy controls, measured clinical symptoms by using the Positive and Negative Syndrome Scale and performed cognitive tests using the MATRICS Consensus Cognitive Battery (MCCB). Plasma levels of tryptophan, kynurenine, and KYNA were determined by high-performance liquid chromatography-tandem mass spectrometry. Results: We found that plasma KYNA levels were significantly higher in patients than in healthy controls (p=0.009). The cognitive performance of patients in the total MCCB scores and the scores of all subscales were significantly lower than those in healthy controls (all P < 0.01). Correlation analysis showed that KYNA levels were negatively correlated with attention/vigilance (r=-0.457, p=0.019) and social cognition (r=-0.481, p=0.013) only in SCZ patients. Conclusion: Our results indicate that elevated plasma KYNA levels may serve as a biomarker of cognitive impairment in SCZ patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available